Gastric Neuroendocrine Tumor Treatment and Survival Outcomes Is Determined by Facility Type

Gastric neuroendocrine tumors (gNETs) are rare cancers affecting roughly 7 in 100,000 people in the USA, and surgery is thought to offer a survival advantage when possible. We aim to determine if treatment facility (academic vs community hospital) plays a role in treatment and survival outcomes of patients with gNET.

Source: Journal of the American College of Surgeons - October 22, 2021 Category: Surgery Authors: Rebecca Platoff, Johanna J. Lou, Kathryn Bush, Clara Zhu, John Gaughan, Young K. Hong Tags: Surgical Oncology Source Type: research